Published in Int J Cancer on December 15, 2001
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol (2005) 1.16
Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol (2008) 1.15
Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des (2010) 1.13
Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA). Genome Med (2012) 1.11
Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A (2013) 1.06
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol (2010) 1.00
New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin Ther Targets (2008) 0.97
Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett (2008) 0.92
Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells. Mini Rev Med Chem (2012) 0.86
Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride. Acad Radiol (2011) 0.86
The many "faces" of copper in medicine and treatment. Biometals (2014) 0.85
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs (2013) 0.84
Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry. Curr Med Chem (2010) 0.83
Wilson disease and hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2008) 0.83
New applications of old metal-binding drugs in the treatment of human cancer. Front Biosci (Schol Ed) (2012) 0.83
Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration. PLoS One (2013) 0.81
Pharmacological activity of metal binding agents that alter copper bioavailability. Dalton Trans (2015) 0.79
Complex N-acetylation of triethylenetetramine. Drug Metab Dispos (2011) 0.76
A benzothiazole alkyne fluorescent sensor for Cu detection in living cell. Bioorg Med Chem Lett (2012) 0.75
D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress. Free Radic Biol Med (2017) 0.75
A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance. J Cancer (2017) 0.75
Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action. PLoS One (2017) 0.75
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09
In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol (1981) 3.34
Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun (2001) 2.63
Occurrence of N-nonsubstituted glucosamine residues in peptidoglycan of lysozyme-resistant cell walls from Bacillus cereus. J Biol Chem (1972) 2.45
Regulation of SOS functions: purification of E. coli LexA protein and determination of its specific site cleaved by the RecA protein. Cell (1981) 2.20
Studies on the effects of laminin, E-8 fragment of laminin and synthetic laminin peptides PA22-2 and YIGSR on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression. Lab Invest (1994) 2.07
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med (1990) 2.05
Embryotoxic effects of ethylene glycol monomethyl ether in mice. Toxicology (1981) 1.95
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology (2001) 1.92
Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J Biol Chem (1998) 1.86
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res (1996) 1.81
Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem (1990) 1.69
Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer (1993) 1.68
Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest (1999) 1.67
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut (2003) 1.60
Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology (2000) 1.59
Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology (1997) 1.59
Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr (2001) 1.55
Large optical nonlinearity of semiconducting single-walled carbon nanotubes under resonant excitations. Phys Rev Lett (2005) 1.53
Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer (2008) 1.53
Relationship between lipase and esterase. J Biochem (1968) 1.51
Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. J Gastroenterol (2001) 1.50
Ethanol-induced vasoconstriction causes focal hepatocellular injury in the isolated perfused rat liver. Hepatology (1992) 1.50
pp60c-src activation in lung adenocarcinoma. Eur J Cancer (2003) 1.49
A quantitative analysis of hemodynamic effects of the right ventricle included in the circulation of the Fontan procedure. Circulation (1991) 1.49
Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets. Am J Hematol (1990) 1.46
The validity of a hyperventilation test for an investigation of autonomic failure: assessment in patients with multiple system atrophy and Parkinson's disease. Int J Clin Pract (2006) 1.45
[Photographic estimation of corneal diameter]. Nihon Ganka Kiyo (1971) 1.45
Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion. Intern Med (1997) 1.45
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem (1998) 1.41
Advanced endometrial cancer detected at 7 months after childbirth. Gynecol Oncol (1997) 1.41
Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene (2011) 1.41
Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase manifesting as acute renal damage. Intern Med (1998) 1.41
A new class of rat glutathione S-transferase Yrs-Yrs inactivating reactive sulfate esters as metabolites of carcinogenic arylmethanols. J Biol Chem (1990) 1.41
Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res (1999) 1.40
Calculation of nuclear magnetic shieldings using an analytically differentiated relativistic shielding formula. J Chem Phys (2005) 1.39
Microscopic polyangiitis that presented liver dysfunction prior to noted renal manifestations. Intern Med (2000) 1.39
Negative U wave: a highly specific but poorly understood sign of heart disease. Am J Cardiol (1982) 1.38
Dynamics of right heart flow in patients after Fontan procedure. Circulation (1984) 1.37
Crystal structure of N-carbamyl-D-amino acid amidohydrolase with a novel catalytic framework common to amidohydrolases. Structure (2000) 1.36
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther (2007) 1.35
Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene (1998) 1.33
Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci U S A (1991) 1.33
Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol (1987) 1.32
Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer (2008) 1.32
Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. Aliment Pharmacol Ther (2006) 1.31
Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron (1994) 1.30
Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene (1997) 1.27
Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr (2001) 1.27
Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer (2002) 1.27
Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun (1988) 1.27
Metabolic abnormalities associated with postoperative organ failure. A redox theory. Arch Surg (1983) 1.27
The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res (2001) 1.26
Relationship between Symptom Development and Actual Sites of Infection in Leaves of Anthurium Inoculated with a Bioluminescent Strain of Xanthomonas campestris pv. dieffenbachiae. Appl Environ Microbiol (1996) 1.26
Clinicopathological features of hepatocellular carcinoma--comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology (1984) 1.24
Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem (1999) 1.24
Rhythmic expression of BMAL1 mRNA is altered in Clock mutant mice: differential regulation in the suprachiasmatic nucleus and peripheral tissues. Biochem Biophys Res Commun (2000) 1.23
Selective inhibition of platelet lipoxygenase by baicalein. Biochem Biophys Res Commun (1982) 1.22
Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res (2000) 1.20
Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat (1998) 1.19
Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology (1992) 1.19
Constipation, laxative use and risk of colorectal cancer: The Miyagi Cohort Study. Eur J Cancer (2004) 1.19
Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis (2000) 1.18
Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol (2000) 1.18
Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer (2008) 1.18
Circulatory maintenance with a single artificial heart. Trans Am Soc Artif Intern Organs (1984) 1.17
Purification, molecular cloning, and expression of lipase from Pseudomonas aeruginosa. Arch Biochem Biophys (1992) 1.16
Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. Arch Orthop Trauma Surg (2000) 1.16